WO2006017698A3 - Novel statin pharmaceutical compositions and related methods of treatment - Google Patents

Novel statin pharmaceutical compositions and related methods of treatment Download PDF

Info

Publication number
WO2006017698A3
WO2006017698A3 PCT/US2005/027815 US2005027815W WO2006017698A3 WO 2006017698 A3 WO2006017698 A3 WO 2006017698A3 US 2005027815 W US2005027815 W US 2005027815W WO 2006017698 A3 WO2006017698 A3 WO 2006017698A3
Authority
WO
WIPO (PCT)
Prior art keywords
omega
treatment
pharmaceutical compositions
related methods
solutions
Prior art date
Application number
PCT/US2005/027815
Other languages
French (fr)
Other versions
WO2006017698A2 (en
Inventor
Hector Guzman
Oern Almarsson
Julius Remenar
Original Assignee
Transform Pharmaceuticals Inc
Hector Guzman
Oern Almarsson
Julius Remenar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc, Hector Guzman, Oern Almarsson, Julius Remenar filed Critical Transform Pharmaceuticals Inc
Priority to BRPI0514189-3A priority Critical patent/BRPI0514189A/en
Priority to CA002576196A priority patent/CA2576196A1/en
Priority to NZ552389A priority patent/NZ552389A/en
Priority to JP2007525011A priority patent/JP2008509154A/en
Priority to EP05778295A priority patent/EP1786414A4/en
Priority to MX2007001553A priority patent/MX2007001553A/en
Priority to AU2005271413A priority patent/AU2005271413A1/en
Publication of WO2006017698A2 publication Critical patent/WO2006017698A2/en
Publication of WO2006017698A3 publication Critical patent/WO2006017698A3/en
Priority to IL180517A priority patent/IL180517A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention provides novel omega-3 oil solutions of one or more statins. These solutions are readily bioavailable. Notably, because the solutions of the invention contain an omega-3 oil as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. The invention also provides novel salts of one or more statins.
PCT/US2005/027815 2004-08-06 2005-08-05 Novel statin pharmaceutical compositions and related methods of treatment WO2006017698A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0514189-3A BRPI0514189A (en) 2004-08-06 2005-08-05 statin pharmaceutical compositions and related treatment methods
CA002576196A CA2576196A1 (en) 2004-08-06 2005-08-05 Novel statin pharmaceutical compositions and related methods of treatment
NZ552389A NZ552389A (en) 2004-08-06 2005-08-05 Statin pharmaceutical compositions and related methods of treatment
JP2007525011A JP2008509154A (en) 2004-08-06 2005-08-05 Novel statin drug compositions and related treatment methods
EP05778295A EP1786414A4 (en) 2004-08-06 2005-08-05 Novel statin pharmaceutical compositions and related methods of treatment
MX2007001553A MX2007001553A (en) 2004-08-06 2005-08-05 Novel statin pharmaceutical compositions and related methods of treatment.
AU2005271413A AU2005271413A1 (en) 2004-08-06 2005-08-05 Novel statin pharmaceutical compositions and related methods of treatment
IL180517A IL180517A0 (en) 2004-08-06 2007-01-02 Novel statin pharmaceutical compositions and related methods of treatment

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US59954304P 2004-08-06 2004-08-06
US60/599,543 2004-08-06
US62351804P 2004-10-29 2004-10-29
US60/623,518 2004-10-29
US65598205P 2005-02-24 2005-02-24
US60/655,982 2005-02-24

Publications (2)

Publication Number Publication Date
WO2006017698A2 WO2006017698A2 (en) 2006-02-16
WO2006017698A3 true WO2006017698A3 (en) 2006-07-06

Family

ID=35839927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027815 WO2006017698A2 (en) 2004-08-06 2005-08-05 Novel statin pharmaceutical compositions and related methods of treatment

Country Status (11)

Country Link
US (1) US7642287B2 (en)
EP (1) EP1786414A4 (en)
JP (1) JP2008509154A (en)
KR (1) KR20070038553A (en)
AU (1) AU2005271413A1 (en)
BR (1) BRPI0514189A (en)
CA (1) CA2576196A1 (en)
IL (1) IL180517A0 (en)
MX (1) MX2007001553A (en)
NZ (1) NZ552389A (en)
WO (1) WO2006017698A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG155189A1 (en) * 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
US20090239927A1 (en) * 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
EA014420B1 (en) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
MX2007011031A (en) * 2005-03-08 2008-04-21 Reliant Pharmaceuticals Inc Treatment with statin and omega-3 fatty acids and a combination product thereof.
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
JP2009515816A (en) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド Novel formulations comprising fenofibrate and statins and related methods of treatment
EP2081550B2 (en) 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
US20080299187A1 (en) * 2007-06-01 2008-12-04 Joar Opheim Substances for Reducing Occurence of Major Cardiac Events in Humans
ITMI20072142A1 (en) * 2007-11-08 2009-05-09 Yervant Zarmanian PHARMACEUTICAL COMPOSITIONS CONTAINING STATIN AND OMEGA-3 FATTY ACID DERIVATIVES
ES2632967T3 (en) 2008-09-02 2017-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of use thereof
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
KR20140007973A (en) 2009-02-10 2014-01-20 아마린 파마, 인크. Methods of treating hypertriglyceridemia
EP2400840A4 (en) * 2009-02-24 2012-08-01 Madeira Therapeutics Liquid statin formulations
CA3065860A1 (en) 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US20100239660A1 (en) * 2009-03-19 2010-09-23 Doughman Scott D Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions
PT2424356T (en) 2009-04-29 2017-11-23 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition and methods of using same
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BRPI1011883A2 (en) 2009-06-15 2016-09-13 Amarin Pharma Inc use of triglyceride-lowering compositions without elevating ldl-c levels in a patient under concomitant statin treatment
EA020944B1 (en) * 2009-07-24 2015-02-27 Эгиш Дьёдьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг Crystalline form i rosuvastatin zinc salt
BR122019016628B8 (en) * 2009-09-23 2021-07-27 Amarin Corp Plc use of a composition comprising an atorvastatin hydroxy derivative or pharmaceutically acceptable salt thereof and an oil comprising ethyl eicosapentaenoate or ethyl docosahexaenoate for the manufacture of a medicament for the treatment of a cardiovascular disease
EP2488022B1 (en) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
US8609138B2 (en) 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
AR082930A1 (en) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As COMPOSITIONS THAT INCLUDE AN OILY MIXTURE OF FATTY ACIDS, A TENSIOACTIVE AND A STATIN
US20140004186A1 (en) * 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US20150272920A1 (en) * 2011-02-16 2015-10-01 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
IN2014DN06125A (en) * 2012-01-06 2015-08-14 Omthera Pharmaceuticals Inc
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
EP2827839B1 (en) 2012-03-20 2019-02-27 Particle Dynamics International, LLC Gelling agent-based dosage form
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
EP3072510B1 (en) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
JP6173437B2 (en) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド Statins and omega-3 fatty acid compositions
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
BR112014029079B1 (en) 2012-05-22 2022-07-26 Kuhnil Pharm. Co., Ltd PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
ES2846176T3 (en) 2012-06-29 2021-07-28 Amarin Pharmaceuticals Ie Ltd Methods to reduce the risk of a cardiovascular event in a subject taking statins using eicosapentaenoic acid ethyl ester
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
KR102108154B1 (en) 2017-02-08 2020-05-07 (주)동구바이오제약 Pharmaceutical composition containing omega-3 fatty acid and HMG-CoA reductase inhibitor with improved bioavailability
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3750536A1 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
WO2021074118A1 (en) * 2019-10-15 2021-04-22 Hermes Arzneimittel Gmbh Liquid omega-3 fatty acid compositions for direct oral administration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231939A (en) * 1979-11-26 1980-11-04 Miles Laboratories, Inc. 2,5-Dioxo-3H,6H-furo[(3,2-b]furan-3a,6a-diacetic acid and salts thereof
EP1157692A1 (en) * 2000-05-22 2001-11-28 Quatex N.V. Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
US20020068095A1 (en) * 2000-12-01 2002-06-06 Chen Qi Cholesterol lowering supplement
US20050032757A1 (en) * 2003-08-06 2005-02-10 Cho Suk H. Nutritional supplements

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (en) * 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) * 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
FI94339C (en) * 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
IT1270594B (en) * 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
CA2313024C (en) * 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
SI20070A (en) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE
SI20305A (en) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Pravastatin sodium salt crystals
SI20109A (en) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
EP1140036A2 (en) 1998-12-18 2001-10-10 Abbott Laboratories Novel formulations comprising lipid-regulating agents
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GR990100388A (en) 1999-11-09 2001-07-31 PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND A FIBRIC ACID DERIVATIVE, PROVIDING FOR PATIENT'S COMPLIANCE AND ANTIPATED TO RETAIN EFFICACY, IMPROVE SAFETY AND REDUCE....
CZ20021998A3 (en) 1999-12-14 2003-02-12 Biogal Gyogyszergyar Rt. Novel forms of pravastatin sodium salt
EP2382970B1 (en) * 2000-04-10 2013-01-09 Teva Pharmaceutical Industries, Ltd. Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids
SK16982002A3 (en) * 2000-06-09 2003-04-01 Lek Pharmaceuticals D. D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
CZ20031166A3 (en) 2000-10-05 2004-04-14 Biogal Gyogyszergyar Rt Pravastatin sodium salt that is substantially free of pravastatin lactone and epi-pravastatin as well as composition based thereon
JP3236282B1 (en) * 2000-10-16 2001-12-10 三共株式会社 How to purify pravastatin
AU3651102A (en) * 2000-11-29 2002-06-11 Smithkline Beecham Corp Composition containing statins and calcium for improved cardiovascular health
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
ES2284646T3 (en) * 2001-02-22 2007-11-16 Jagotec Ag STATIN-FIBRATE COMBINATIONS WITH SECONDARY EFFECTS IN REDUCED FAST-FASTING.
CA2450238A1 (en) 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
EP1404303A4 (en) 2001-06-21 2006-03-15 Andrx Pharmaceuticals Inc Stable pharmaceutical compositions containing pravastatin
KR20040026705A (en) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 Processes for preparing calcium salt forms of statins
SK1402004A3 (en) 2001-08-16 2005-01-03 Teva Pharmaceutical Industries Ltd. Process for preparing calcium salt forms of statins
KR100407758B1 (en) * 2001-08-27 2003-12-01 씨제이 주식회사 Process of lactonization in the preparation of statins
KR100414334B1 (en) * 2001-09-29 2004-01-07 코바이오텍 (주) Process for preparing Pravastatin sodium
US6973191B2 (en) 2001-11-02 2005-12-06 Activcard System and method for generating symmetric keys within a personal security device having minimal trust relationships
US20040018248A1 (en) * 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
BR0307720A (en) * 2002-02-14 2005-01-25 Ranbaxi Lab Ltd Alkali Metal Addition Stabilized Atorvastatin Formulations, Method for Producing a Pharmaceutical Formulation and Stabilizing Said Formulation
ES2315510T3 (en) 2002-06-13 2009-04-01 Novartis Ag STATIN CALCIUM SALTS DERIVED FROM INDOL.
US6844892B2 (en) * 2002-06-13 2005-01-18 Pentax Corporation Multi-beam scanning device
MXPA05000050A (en) 2002-07-03 2005-04-08 Esperion Therapeutics Inc Compositions comprising panthetine for the treatment of dyslipidemia.
ES2342885T3 (en) 2003-08-06 2010-07-16 Galephar M/F STABLE CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOFIBRATE AND PRAVASTATIN.
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
RU2343905C2 (en) 2003-10-10 2009-01-20 Лайфсайкл Фарма А/С Solid dosed out forms including fibrat and statin
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
JP4839221B2 (en) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Combination therapy combination to increase HDL
CA2553988A1 (en) 2004-01-20 2005-07-28 Panacea Biotec Ltd. Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof
CA2563128A1 (en) 2004-04-28 2005-11-10 Unilever Plc Edible oil containing statins
US20050267197A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
US20050281868A1 (en) 2004-06-21 2005-12-22 Fairfield Clinical Trials, Llc Transdermal delivery system for statin combination therapy
ITRM20040395A1 (en) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti COMPOSITION INCLUDING STATINES AND FATTY ACIDS OMEGA 3.
CN101014254A (en) 2004-08-23 2007-08-08 荷兰联合利华有限公司 Composition comprising statin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231939A (en) * 1979-11-26 1980-11-04 Miles Laboratories, Inc. 2,5-Dioxo-3H,6H-furo[(3,2-b]furan-3a,6a-diacetic acid and salts thereof
EP1157692A1 (en) * 2000-05-22 2001-11-28 Quatex N.V. Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
US20020068095A1 (en) * 2000-12-01 2002-06-06 Chen Qi Cholesterol lowering supplement
US20050032757A1 (en) * 2003-08-06 2005-02-10 Cho Suk H. Nutritional supplements

Also Published As

Publication number Publication date
WO2006017698A2 (en) 2006-02-16
NZ552389A (en) 2009-05-31
EP1786414A2 (en) 2007-05-23
CA2576196A1 (en) 2006-02-16
EP1786414A4 (en) 2008-04-09
AU2005271413A1 (en) 2006-02-16
JP2008509154A (en) 2008-03-27
MX2007001553A (en) 2008-03-07
KR20070038553A (en) 2007-04-10
US7642287B2 (en) 2010-01-05
US20060034815A1 (en) 2006-02-16
BRPI0514189A (en) 2008-06-03
IL180517A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2006017698A3 (en) Novel statin pharmaceutical compositions and related methods of treatment
WO2006017692A3 (en) Novel fenofibrate formulations and related methods of treatment
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2002094210A3 (en) Cosmetic agents
IL164434A0 (en) Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis sinclair pharmaceuticals limited
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
WO2007146248A3 (en) Stable laquinimod preparations
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2004041269A3 (en) New use for pharmaceutical composition
MY145074A (en) Thiazolidin-4-one derivatives
WO2005117895A8 (en) Compositions comprising meloxicam
BR0308613A (en) Combination of Organic Compounds
BR0210139A (en) Pharmaceutical Compositions
WO2006123031A3 (en) Pharmaceutical composition comprising an oleaginous ointment and vitamin d or the derivatives thereof in solubilised form
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
HUP0301819A2 (en) Use of essential oils for combating gi tract infection by helicobacter-like organisms
WO2003024943A3 (en) Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis
TW200637542A (en) Lipase inhibitor, preventing and treating agent of skin disease
EP1944027A4 (en) Pharmaceutical composition for treatment or prevention of nephritis and method for producing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 180517

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 552389

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005271413

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12007500126

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 187/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005271413

Country of ref document: AU

Date of ref document: 20050805

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007525011

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2005271413

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2576196

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001553

Country of ref document: MX

Ref document number: 200580026639.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077003811

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007/01916

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005778295

Country of ref document: EP

Ref document number: 2007107797

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020077003811

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005778295

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0514189

Country of ref document: BR